Alternatives to Plaquenil If You Can't Fill Your Prescription

Plaquenil (hydroxychloroquine) is a cornerstone treatment for lupus and rheumatoid arthritis. When a supply shortage or insurance issue makes it temporarily unavailable, patients and providers face a difficult question: what do you do next? This guide covers the most commonly considered alternatives, along with the key factors that influence the choice.

Important: Do not switch medications on your own. Any change to your DMARD therapy should be made in consultation with your rheumatologist or prescribing physician. This article is for educational purposes only.

Why Plaquenil Is Hard to Replace

Hydroxychloroquine occupies a unique niche in autoimmune treatment. It has a favorable safety profile, is not immunosuppressive (it doesn't increase infection risk the way biologics do), works well in combination with other DMARDs, and has a long track record of protecting lupus patients from organ damage over time. No single alternative drug replicates all of these properties.

For this reason, rheumatologists typically try hard to find alternative pharmacy sources before switching medications. However, if a true shortage forces the issue, the following options may be considered.

Methotrexate

Methotrexate is the most widely used conventional DMARD for rheumatoid arthritis and is often used alongside Plaquenil in combination therapy. For RA patients who are switching off Plaquenil, methotrexate is typically the first-line consideration. It is taken weekly (not daily), requires regular blood monitoring (CBC and liver function tests), and is contraindicated in pregnancy.

For lupus, methotrexate is used off-label and is generally considered less effective than hydroxychloroquine for systemic protection. It's more useful for specific manifestations like skin lupus or joint symptoms.

Sulfasalazine

Sulfasalazine (brand name Azulfidine) is another conventional DMARD used for rheumatoid arthritis. The American College of Rheumatology recommends sulfasalazine as the primary alternative to hydroxychloroquine for patients with low disease activity RA. It is taken twice daily and may also be used in combination with methotrexate. It requires G6PD testing before use, since it can cause hemolytic anemia in G6PD-deficient patients (a concern that also applies to hydroxychloroquine itself).

Leflunomide (Arava)

Leflunomide (brand name Arava) is a DMARD used for rheumatoid arthritis and, less commonly, psoriatic arthritis. It is considered a third-line option after sulfasalazine and methotrexate. Leflunomide is taken once daily and requires blood monitoring. A significant limitation is its very long half-life—it can persist in the body for up to two years—and it requires a drug elimination procedure (cholestyramine or activated charcoal) if it needs to be cleared quickly, such as in pregnancy planning.

Chloroquine (Aralen)

Chloroquine is the chemical cousin of hydroxychloroquine and was the original antimalarial used for lupus before Plaquenil became standard. Some rheumatologists will consider a temporary switch to chloroquine when hydroxychloroquine is unavailable, since both are 4-aminoquinoline compounds with similar mechanisms. However, chloroquine has a higher risk of retinal toxicity and is used much less frequently in modern practice.

Biologic DMARDs (for RA)

For rheumatoid arthritis patients with moderate-to-severe disease who cannot tolerate conventional DMARDs, biologic therapies such as TNF inhibitors (adalimumab/Humira, etanercept/Enbrel), JAK inhibitors (tofacitinib/Xeljanz, baricitinib/Olumiant), or IL-6 inhibitors (tocilizumab/Actemra) may be considered. These are significantly more expensive and carry higher infection risks, so they are not typically first-line for patients who only needed Plaquenil due to a shortage—but they may be appropriate for patients with more severe disease.

What About Lupus Patients?

For systemic lupus erythematosus (SLE), replacing hydroxychloroquine is particularly complex. HCQ is considered a disease-modifying background therapy that reduces flare risk, prevents organ damage, and may even reduce cardiovascular risk in lupus patients. If a lupus patient must temporarily stop, their rheumatologist may increase monitoring, consider a short course of corticosteroids to bridge, or discuss newer biologic options such as belimumab (Benlysta) for eligible patients.

Before Switching: Try to Find More Plaquenil

Most of the time, an apparent shortage is a local supply issue rather than a nationwide one. Before asking about alternatives, try calling multiple pharmacies or using medfinder to have pharmacies in your area checked for availability. Switching DMARDs carries real risks and transition time, whereas finding a different pharmacy may solve the problem immediately.

See also: How to Find Plaquenil in Stock Near You for step-by-step pharmacy search tips.